JAMA 340B viewpoint
On the day a group of bipartisan Senators requested feedback from stakeholders, an influential academic and his colleagues published a series of recommendations to reform the 340B program in JAMA

On Deadline Day for Senate Feedback, Researchers in JAMA Urge 340B Provider Reporting, Tightening Eligibility, Preventing Drug Overcharges

A high-profile researcher and colleagues are urging a range of changes to the 340B program, including new provisions on transparency, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.